Circulating tumor cells in the diagnosis and management of pancreatic cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 2, 2012, Pages 350-356

  Cen, Putao ^a   Ni, Xiaoling ^a,b   Yang, Jingxuan ^a   Graham, David Y ^c   Li, Min ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b FUDAN UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Circulating tumor cells; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; MESSENGER RNA; TRASTUZUMAB;

ADVANCED CANCER; ANTIBODY DETECTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL SUBPOPULATION; CIRCULATING TUMOR CELL; CLINICAL EFFECTIVENESS; DISTANT METASTASIS; DRUG EFFECT; DRUG EFFICACY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC VARIABILITY; HUMAN; IMMUNOASSAY; LUNG CANCER; METASTASIS; PANCREAS CANCER; PANCREATICODUODENECTOMY; PERSONALIZED MEDICINE; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT PLANNING; TUMOR SEEDING;

CELL SEPARATION; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS;

EID: 84862705627     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.05.007     Document Type: Review

References (57)

1. Onuigbo W.I. An index of the fate of circulating cancer cells. Lancet 1963, 2:828-831.
2. Robinson K.P., Mc G.R., Mc G.E. Circulating cancer cells in patients with lung tumors. Surgery 1963, 53:630-636.
3. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 1869, 14:146-147.
4. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., Tibbe A.G., Uhr J.W., Terstappen L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10:6897-6904.
5. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W., Meropol N.J. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:3213-3221.
6. Wong S.C., Chan C.M., Ma B.B., Hui E.P., Ng S.S., Lai P.B., Cheung M.T., Lo E.S., Chan A.K., Lam M.Y., Au T.C., Chan A.T. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin. Cancer Res. 2009, 15:1005-1012.
7. Uen Y.H., Lu C.Y., Tsai H.L., Yu F.J., Huang M.Y., Cheng T.L., Lin S.R., Wang J.Y. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann. Surg. Oncol. 2008, 15:2120-2128.
8. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W., Hayes D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791.
9. Pachmann K., Camara O., Kavallaris A., Krauspe S., Malarski N., Gajda M., Kroll T., Jorke C., Hammer U., Altendorf-Hofmann A., Rabenstein C., Pachmann U., Runnebaum I., Hoffken K. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J. Clin. Oncol. 2008, 26:1208-1215.
10. Danila D.C., Heller G., Gignac G.A., Gonzalez-Espinoza R., Anand A., Tanaka E., Lilja H., Schwartz L., Larson S., Fleisher M., Scher H.I. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 2007, 13:7053-7058.
11. Morgan T.M., Lange P.H., Porter M.P., Lin D.W., Ellis W.J., Gallaher I.S., Vessella R.L. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin. Cancer Res. 2009, 15:677-683.
12. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., Digumarthy S., Muzikansky A., Irimia D., Settleman J., Tompkins R.G., Lynch T.J., Toner M., Haber D.A. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 2008, 359:366-377.
13. Fan T., Zhao Q., Chen J.J., Chen W.T., Pearl M.L. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol. Oncol. 2009, 112:185-191.
14. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61:212-236.
15. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
16. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
17. Shi S., Yao W., Xu J., Long J., Liu C., Yu X. Combinational therapy: new hope for pancreatic cancer?. Cancer Lett. 2012, 317:127-135.
18. Ni X., Yang J., Li M. Imaging-Guided Curative Surgical Resection of Pancreatic Cancer in a Xenograft Mouse Model. Cancer Lett. 2012, 10.1016/j.canlet.2012.05.013.
19. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am. J. Gastroenterol. 1990, 85:350-355.
20. Duffy M.J., Sturgeon C., Lamerz R., Haglund C., Holubec V.L., Klapdor R., Nicolini A., Topolcan O., Heinemann V. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann. Oncol. 2010, 21:441-447.
21. Goggins M. Molecular markers of early pancreatic cancer. J. Clin. Oncol. 2005, 23:4524-4531.
22. Kurihara T., Itoi T., Sofuni A., Itokawa F., Tsuchiya T., Tsuji S., Ishii K., Ikeuchi N., Tsuchida A., Kasuya K., Kawai T., Sakai Y., Moriyasu F. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J. Hepatobiliary Pancreat. Surg. 2008, 15:189-195.
23. van de Stolpe A., Pantel K., Sleijfer S., Terstappen L.W., den Toonder J.M. Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res. 2011, 71:5955-5960.
24. Nagrath S., Sequist L.V., Maheswaran S., Bell D.W., Irimia D., Ulkus L., Smith M.R., Kwak E.L., Digumarthy S., Muzikansky A., Ryan P., Balis U.J., Tompkins R.G., Haber D.A., Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
25. Stott S.L., Hsu C.H., Tsukrov D.I., Yu M., Miyamoto D.T., Waltman B.A., Rothenberg S.M., Shah A.M., Smas M.E., Korir G.K., Floyd F.P., Gilman A.J., Lord J.B., Winokur D., Springer S., Irimia D., Nagrath S., Sequist L.V., Lee R.J., Isselbacher K.J., Maheswaran S., Haber D.A., Toner M. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18392-18397.
26. Sergeant G., Roskams T., van Pelt J., Houtmeyers F., Aerts R., Topal B. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer 2011, 11:47.
27. Hoffmann K., Kerner C., Wilfert W., Mueller M., Thiery J., Hauss J., Witzigmann H. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J. Gastroenterol. 2007, 13:257-263.
28. Soeth E., Grigoleit U., Moellmann B., Roder C., Schniewind B., Kremer B., Kalthoff H., Vogel I. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J. Cancer Res. Clin. Oncol. 2005, 131:669-676.
29. Srovnal J., Benedikova A., Klos D., Lovecek M., Havlik R., Radova L., Cwiertka K., Hajduch M. The detection of circulating tumor cells is a negative prognostic factor in pancreatic cancer in: AACR 102nd Annual Meeting 2011. Cancer Research 2011, vol. 71, Issue 8, Supplement 1.
30. Albuquerque A.d., Kubisch I., Ernst D., Breier G., Kaul S., Fersis N. Prognostic significance of multimarker circulating tumor cell analysis in patients with advanced pancreatic cancer. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2011, vol. 29. Post-Meeting Edition.
31. Gascoyne P.R., Noshari J., Anderson T.J., Becker F.F. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 2009, 30:1388-1398.
32. Hsieh H.B., Marrinucci D., Bethel K., Curry D.N., Humphrey M., Krivacic R.T., Kroener J., Kroener L., Ladanyi A., Lazarus N., Kuhn P., Bruce R.H., Nieva J. High speed detection of circulating tumor cells. Biosens. Bioelectron. 2006, 21:1893-1899.
33. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009, 1:12-25.
34. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
35. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
36. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315:1650-1659.
37. Wallerand H., Robert G., Pasticier G., Ravaud A., Ballanger P., Reiter R.E., Ferriere J.M. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol. Oncol. 2010, 28:473-479.
38. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
39. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. 2005, 5:744-749.
40. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R., Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009, 11:R46.
41. Li L., Xie T. Stem cell niche: structure and function. Annu. Rev. Cell Dev. Biol. 2005, 21:605-631.
42. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
43. Korkaya H., Liu S., Wicha M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Invest. 2011, 121:3804-3809.
44. Dontu G., Jackson K.W., McNicholas E., Kawamura M.J., Abdallah W.M., Wicha M.S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004, 6:R605-R615.
45. Korkaya H., Liu S., Wicha M.S. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin. Cancer Res. 2011, 17:6125-6129.
46. Iinuma H., Watanabe T., Mimori K., Adachi M., Hayashi N., Tamura J., Matsuda K., Fukushima R., Okinaga K., Sasako M., Mori M. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J. Clin. Oncol. 2011, 29:1547-1555.
47. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., Korkaya H., Heath A., Dutcher J., Kleer C.G., Jung Y., Dontu G., Taichman R., Wicha M.S. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71:614-624.
48. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., Kamiyama M., Hruban R.H., Eshleman J.R., Nowak M.A., Velculescu V.E., Kinzler K.W., Vogelstein B., Iacobuzio-Donahue C.A. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
49. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., Leach S.D., Stanger B.Z. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
50. Norton L., Massague J. Is cancer a disease of self-seeding?. Nat. Med. 2006, 12:875-878.
51. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., Massague J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
52. Comen E., Norton L., Massague J. Clinical implications of cancer self-seeding. Nat. Rev. Clin. Oncol. 2011, 8:369-377.
53. Loehrer P.J., Feng Y., Cardenes H., Wagner L., Brell J.M., Cella D., Flynn P., Ramanathan R.K., Crane C.H., Alberts S.R., Benson A.B. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J. Clin. Oncol. 2011, 29:4105-4112.
54. Husemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., Forni G., Eils R., Fehm T., Riethmuller G., Klein C.A. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
55. Shigematsu H., Kadoya T., Kobayashi Y., Kajitani K., Sasada T., Emi A., Masumoto N., Haruta R., Kataoka T., Oda M., Arihiro K., Okada M. A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer. World J. Surg. Oncol. 2011, 9:146.
56. Li M., Zhang Y., Liu Z., Bharadwaj U., Wang H., Wang X., Zhang S., Liuzzi J.P., Chang S.M., Cousins R.J., Fisher W.E., Brunicardi F.C., Logsdon C.D., Chen C., Yao Q. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18636-18641.
57. Li M., Zhang Y., Bharadwaj U., Zhai Q.J., Ahern C.H., Fisher W.E., Brunicardi F.C., Logsdon C.D., Chen C., Yao Q. Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts. Clin. Cancer Res. 2009, 15:5993-6001.